http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-586123-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9cc21c102a2aa9597ba6a7a2ea8a3cd
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
filingDate 2008-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80662e471f981d90c4ee436b30740f39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fe9a3bed049a5bae680d0747bfb51d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7621599838dbc2d2897d559902569574
publicationDate 2012-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-586123-A
titleOfInvention Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
abstract Disclosed is the use of 4-iodo-3-nitrobenzamide (pictured), or a metabolite or a pharmaceutically acceptable salt thereof, and at least one topoisomerase inhibitor for the treatment of metastatic ovarian cancer. Suitable topoisomerase inhibitors include topotecan, irinotecan, lurtotecan, exatecan and camptothecin.
priorityDate 2007-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60700
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415853116
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9796068
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24360
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60956
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419481343
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502669
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID151115
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419497994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535834
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419516305

Total number of triples: 40.